AASLD News

Data from a new study presented this week at The Liver Meeting® – held by the American Association for the Study of Liver Diseases – found fewer new cases of hepatitis C infection (commonly called HCV), despite very high rates of other sexually-transmitted infections, in HIV-negative men who have sex with men who take pre-exposure prophylaxis (PrEP) treatments.

Media Contact: Caroline Laurin Phone: (703) 299-9766 Onsite phone: (617)-954-2945 Email: media@aasld.org Boston – Data from a new study presented this week at The Liver Meeting® – held by the American Association for the Study of Liver Diseases and funded by the AASLD Foundation – found that less than two percent of pregnant women with cirrhosis had liver decompensation within one year of delivery

Data from a new study presented this week at The Liver Meeting® – held by the American Association for the Study of Liver Diseases – found that cirrhosis patients in the U.S. have substantial financial burden, and this is associated with underuse of surveillance – the ongoing collection of health information– for hepatocellular carcinoma (HCC). Improved intervention strategies are needed to

HCVguidelines.org — a website developed by the American Association for the Study of Liver Diseases and the Infectious Diseases Society of America to provide up-to-date guidance on the management of hepatitis C — was recently revised to reflect important developments in the identification and management of chronic hepatitis C (HCV).

Media Contact: Caroline Laurin Phone: (703) 299-9766 Onsite phone: (415)-978-3601 Email: media@aasld.org San Francisco – Preliminary data from a new study presented this week at The Liver Meeting® – held by the American Association for the Study of Liver Diseases – found that universal screening of pregnant women at risk for hepatitis C virus (commonly called HCV) infection is a more efficient and

Media Contact: Caroline Laurin Phone: (703) 299-9766 Onsite phone: (415) 978-3601 Email: media@aasld.org San Francisco – Data from a new study presented this week at The Liver Meeting® – held by the American Association for the Study of Liver Diseases – found the combination of glecaprevir and pibrentasvir is highly effective and well tolerated in patients with chronic hepatitis C virus (commonly

Media Contact: Caroline Laurin Phone: (703) 299-9766 Onsite phone: (415)-978-3601 Email: media@aasld.org San Francisco – Preliminary data from a new study presented this week at The Liver Meeting® – held by the American Association for the Study of Liver Diseases – found that weight-loss surgery prior to liver transplantation is superior to medical weight loss approaches at achieving sustained

Preliminary data from a new study presented this week at The Liver Meeting® – held by the American Association for the Study of Liver Diseases – found that patients treated with immune checkpoint inhibitors rarely develop severe liver toxicity, but the majority of those who do permanently stop this cancer treatment. None of the patients developed liver failure as a result of this treatment.

Media Contact: Caroline Laurin Phone: (703) 299-9766 Onsite phone: (415)-978-3601 Email: media@aasld.org San Francisco – Data from a new study presented this week at The Liver Meeting® – held by the American Association for the Study of Liver Diseases – found that more than half of pediatric liver transplant recipients are under-immunized at the time of their transplant and are at increased risk

Data from a new study presented this week at The Liver Meeting® – held by the American Association for the Study of Liver Diseases – found that taking a regular aspirin is associated with a dose-dependent reduction in the risk of hepatocellular carcinoma, one of the most common liver cancers.

Media Contact: Caroline Laurin Phone: (703) 299-9766 Onsite phone: (415)-978-3601 Email: media@aasld.org San Francisco – Preliminary data from a new study presented this week at The Liver Meeting® – held by the American Association for the Study of Liver Diseases – found that rates of malignancy occurring outside of the liver were higher in adults with nonalcoholic fatty liver disease than among

Preliminary data from a new study presented this week at The Liver Meeting® – held by the American Association for the Study of Liver Diseases – found that pre-emptive administration of pan-genotypic, direct-acting antiviral therapy prevents chronic hepatitis C virus infection in hepatitis C-negative cardiac transplant patients who receive donor hearts infected with the virus.

Data from a new study presented this week at The Liver Meeting® – held by the American Association for the Study of Liver Diseases – found that a substantial burden of hepatocellular carcinoma (HCC) and cirrhosis-related deaths may be prevented by lifestyle modifications to diet, alcohol use and exercise.

Preliminary data from a new study presented this week at The Liver Meeting® – held by the American Association for the Study of Liver Diseases – found that people who inject drugs who are infected with the hepatitis C virus have high rates of hepatitis C treatment adherence (completion of their treatment), and sustained virologic response. Based on these findings, researchers conclude these